The £17m Biotechnology Building has processed its first commercial-scale batch of antigen, which will be used in a number of new aquaculture vaccines in Benchmark's product pipeline.

Work on the final validation of the facility to ensure compliance with EU Good Manufacturing Practices (GMP) is underway and once fully licensed the increased capacity will allow the Company to significantly expand the number and range of vaccines it produces.

The 2,500-square-metre facility is set to be one of the most capable EU GMP antigen production facilities in Europe.

Benchmark Holdings plc published this content on 17 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 17 October 2017 06:50:03 UTC.

Original documenthttp://www.benchmarkplc.com/articles/new-vaccine-facility-delivers-first-commercial-scale-production/

Public permalinkhttp://www.publicnow.com/view/2DF972861433E5AB282DDF11775E1A069BB7AB54